Biomarkers and their applications for the diagnosis of cerebral infarction and white matter lesions

A biomarker and cerebral infarction technology, applied in disease diagnosis, biological testing, biomaterial analysis, etc., can solve problems such as complicated operation, high cost, and need to move patients

Active Publication Date: 2021-11-30
BAO FENG BIOTECH (BEIJING) CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Imaging methods such as CT and MRI are widely used in the diagnosis of cerebral infarction and white matter lesions, but they have disadvantages such as complicated operation, need to move patients, and high cost. Searching for blood biological indicators that can be indicative of cerebral infarction diagnosis and disease progression It has important clinical value in guiding the treatment of stroke and improving the prognosis of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers and their applications for the diagnosis of cerebral infarction and white matter lesions
  • Biomarkers and their applications for the diagnosis of cerebral infarction and white matter lesions
  • Biomarkers and their applications for the diagnosis of cerebral infarction and white matter lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Model building sample group 116 people (internal population)

[0037] Selected control population: 66 people without a history of cerebral infarction, without abnormality in MRI and normal by clinical evaluation, male to female ratio: 1:1, age range: over 45.

[0038] Patient population: with a history of cerebral infarction, MRI nuclear magnetic resonance examination showed high signal in the white matter of the brain, a total of 50 patients, male to female ratio: 1:1, age range: over 45.

[0039] The collected serum samples of the above population were thawed on ice, and 200 μL of serum was extracted with 600 μL of pre-cooled isopropanol, vortexed with a vortex oscillator (model MX-S, Scilogex, USA) for 1 min, incubated at room temperature for 10 min, and then The extraction mixture was stored overnight at -20°C. After centrifugation at 4000rr for 20min in a refrigerated centrifuge (model D3024R, Scilogex, USA), the supernatant was transferred to a new centrifuge t...

Embodiment 2

[0065] Example 2 External data set, logistic regression model verification

[0066] The model validation sample group is 158 people (external population), including normal people: no history of cerebral infarction, no abnormalities in MRI nuclear magnetic detection, a total of 58 people, male to female ratio: 1:1, age range: 45 and above.

[0067] Patient population: with a history of cerebral infarction, MRI nuclear magnetic resonance examination showed cerebral white matter with high signal, 100 patients, male to female ratio: 1:1 age range: over 45.

[0068] According to the method in Example 1, galactosylceramide, glucosylceramide, β-alpipentol, arborvitene, 1,3Z,6Z,9Z-nonanetetraene, p-cymene, oxalic acid, The content of 3-(stearyloxy group)-4-(trimethylammonium group) butyrate, according to and drawing corresponding ROC curve figure, the result is as follows:

[0069] "Model A" variable is F12+F1, and the result of the ROC curve is as follows Figure 7 , Sensitivity (s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides biomarkers for diagnosing cerebral infarction and white matter lesions and applications thereof. The biomarker is the application of galactosylceramide in the preparation of detection reagents for diagnosing cerebral infarction and white matter lesions. The biomarkers Galactosylceramide combined with glucosylceramide, β‑alpipentol, arborvitene, 1,3Z,6Z,9Z‑nonanetetraene, p-cymene, oxalic acid, 3‑(stearyloxy) ‑4‑(Trimethylammonium) butyrate can be used to judge the risk of cerebral infarction and white matter lesions, and can prevent and prevent cerebral infarction and white matter lesions in advance.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a biomarker for diagnosing cerebral infarction and white matter lesion and its application. Background technique [0002] At present, with the aging of society, the incidence of stroke has increased sharply. Among them, ischemic stroke (cerebral infarction) is caused by ischemic necrosis of brain tissue due to stenosis or occlusion of cerebral arteries, accounting for more than 70% of all strokes. White matter lesion (WML) is a common neurodegenerative disease, the most typical pathological manifestation is damage to the integrity of white matter or demyelination, it can be a neurological disease such as infection, poisoning, degenerative Changes, post-traumatic, cerebral infarction and other secondary manifestations. The disease is common in stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia and other diseases. White ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/32G01N30/34G01N30/72G01N30/86G01N33/50
CPCG01N30/02G01N30/06G01N30/32G01N30/34G01N30/72G01N30/8675G01N33/50G01N2030/062G01N2030/324G01N2800/2871G01N2800/50
Inventor 陈显扬宋王婷张珂韩佳睿薛腾
Owner BAO FENG BIOTECH (BEIJING) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap